Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib Phase 2 in SLE
NCT02708095Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2016
- Primary completion
- Oct 2017
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Antibody-Based Therapeutics
- Countries
- 12
01
Overview
Phase 2, randomised, double-blind trial of baricitinib in systemic lupus erythematosus (SLE) (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: Percentage of Participants Who Achieve Remission of Arthritis and/or Rash Defined by the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) at 24 weeks. Started Mar 2016; status: completed.
02
Drugs
baricitinib
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT02708095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02708095.